{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:08:54Z","timestamp":1792829334413,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cardiac amyloidosis, characterized by extracellular deposition of amyloid fibrils within the myocardium, is an increasingly recognized cause of heart failure. With the advent of disease-modifying therapies, imaging has become central to diagnosis, subtype differentiation, prognostication, and treatment monitoring. This review provides a comprehensive update on multimodality imaging in cardiac amyloidosis, emphasizing its clinical utility across the disease continuum. Echocardiography, technetium-labeled bone scintigraphy, amyloid-specific positron emission tomography, cardiac magnetic resonance, and cardiac computed tomography each contribute uniquely to detecting amyloid burden and assessing cardiac function. In addition to outlining a practical diagnostic approach, we highlight emerging imaging biomarkers for monitoring treatment response and predicting clinical outcomes. The integration of these modalities into clinical practice enhances diagnostic accuracy, enables individualized risk stratification, and supports optimized, evidence-based care for patients with cardiac amyloidosis.<\/jats:p>","DOI":"10.1007\/s12149-025-02092-x","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T19:52:28Z","timestamp":1756151548000},"page":"1037-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-8441","authenticated-orcid":false,"given":"Osamu","family":"Manabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Norikane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Otaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagara","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"2092_CR1","first-page":"396","volume":"36","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Falk RH. Amyloidosis as a systemic disease in context. Can J Cardiol. 2020;36(3):396\u2013407.","journal-title":"Can J Cardiol"},{"issue":"23\u201324","key":"2092_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","volume":"132","author":"D Bonderman","year":"2020","unstructured":"Bonderman D, P\u00f6lzl G, Ablasser K, Agis H, Aschauer S, Auer-Grumbach M, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23\u201324):742\u201361.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"2092_CR3","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368\u201383.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"2092_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12149-023-01878-1","volume":"38","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Manabe O. Current status and perspectives of nuclear cardiology. Ann Nucl Med. 2024;38(1):20\u201330.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"2092_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s12149-021-01650-3","volume":"35","author":"TM Ionescu","year":"2021","unstructured":"Ionescu TM, Jalloul W, Stolniceanu CR, Iacob R, Grecu LP, St\u0103tescu AM, et al. Transthyretin cardiac amyloidosis: a review of the nuclear imaging findings with emphasis on the radiotracers mechanisms. Ann Nucl Med. 2021;35(9):967\u201393.","journal-title":"Ann Nucl Med"},{"issue":"6","key":"2092_CR6","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1007\/s00330-024-11283-5","volume":"35","author":"M Gatti","year":"2025","unstructured":"Gatti M, De Filippo O, Cura Cur\u00e0 G, Dusi V, Di Vita U, Gallone G, et al. Diagnostic accuracy of late iodine enhancement on cardiac CT for myocardial tissue characterization: a systematic review and meta-analysis. Eur Radiol. 2025;35(6):3054\u201367.","journal-title":"Eur Radiol"},{"issue":"6 Pt 1","key":"2092_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101784","volume":"4","author":"NK Bart","year":"2025","unstructured":"Bart NK, Bianchi G, Cuddy SAM, Goyal P, Griffin JM, Hummel SL, et al. Cardiac amyloidosis in older adults with a focus on frailty: JACC: advances expert consensus. JACC Adv. 2025;4(6 Pt 1): 101784.","journal-title":"JACC Adv"},{"issue":"2\u20133","key":"2092_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","volume":"130","author":"JD Sipe","year":"2000","unstructured":"Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000;130(2\u20133):88\u201398.","journal-title":"J Struct Biol"},{"issue":"9","key":"2092_CR9","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84(9):1610\u201371.","journal-title":"Circ J"},{"issue":"4","key":"2092_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-021-01028-8","volume":"23","author":"LK Stern","year":"2021","unstructured":"Stern LK, Kittleson MM. Updates in cardiac amyloidosis diagnosis and treatment. Curr Oncol Rep. 2021;23(4):47.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"2092_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","volume":"16","author":"S Ihne","year":"2019","unstructured":"Ihne S, Morbach C, Obici L, Palladini G, St\u00f6rk S. Amyloidosis in heart failure. Curr Heart Fail Rep. 2019;16(6):285\u2013303.","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"2092_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0080-9","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8(5): 44.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2092_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12891-023-06853-5","volume":"24","author":"E Aldinc","year":"2023","unstructured":"Aldinc E, Campbell C, Gustafsson F, Beveridge A, Macey R, Marr L, et al. Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review. BMC Musculoskelet Disord. 2023;24(1):751.","journal-title":"BMC Musculoskelet Disord"},{"issue":"38","key":"2092_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879\u201387.","journal-title":"Eur Heart J"},{"issue":"4","key":"2092_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","volume":"71","author":"PR Scully","year":"2018","unstructured":"Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71(4):463\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2092_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"issue":"4","key":"2092_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","volume":"3","author":"G Bianchi","year":"2021","unstructured":"Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies. JACC Cardiooncol. 2021;3(4):467\u201387.","journal-title":"JACC Cardiooncol"},{"issue":"11","key":"2092_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"2092_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"23","key":"2092_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","volume":"391","author":"M Fontana","year":"2024","unstructured":"Fontana M, Solomon SD, Kachadourian J, Walsh L, Rocha R, Lebwohl D, et al. CRISPR-Cas9 gene editing with Nexiguran Ziclumeran for ATTR cardiomyopathy. N Engl J Med. 2024;391(23):2231\u201341.","journal-title":"N Engl J Med"},{"issue":"11","key":"2092_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2092_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2092_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","volume":"6","author":"L De Michieli","year":"2024","unstructured":"De Michieli L, Cipriani A, Iliceto S, Dispenzieri A, Jaffe AS. Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis. JACC Cardiooncol. 2024;6(1):1\u201315.","journal-title":"JACC Cardiooncol"},{"issue":"9","key":"2092_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2092_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1515\/cclm-2015-0938","volume":"54","author":"P Mollee","year":"2016","unstructured":"Mollee P, Merlini G. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. Clin Chem Lab Med. 2016;54(6):921\u20137.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"2092_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.11687","volume":"93","author":"T Bochtler","year":"2008","unstructured":"Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica. 2008;93(3):459\u201362.","journal-title":"Haematologica"},{"issue":"4","key":"2092_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","volume":"4","author":"A Cipriani","year":"2022","unstructured":"Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC Cardiooncol. 2022;4(4):458\u201370.","journal-title":"JACC Cardiooncol"},{"issue":"3","key":"2092_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/anec.12036","volume":"18","author":"R Mussinelli","year":"2013","unstructured":"Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(3):271\u201380.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2092_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101279","volume":"49","author":"S Ota","year":"2023","unstructured":"Ota S, Izumiya Y, Kitada R, Nishi T, Taruya A, Wada T, et al. Diagnostic significance of paradoxical left ventricular hypertrophy in detecting cardiac amyloidosis. IJC Heart Vasc. 2023;49: 101279.","journal-title":"IJC Heart Vasc"},{"issue":"4","key":"2092_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","volume":"3","author":"J Hartnett","year":"2021","unstructured":"Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, et al. Electrophysiological manifestations of cardiac amyloidosis. JACC Cardiooncol. 2021;3(4):506\u201315.","journal-title":"JACC Cardiooncol"},{"key":"2092_CR31","doi-asserted-by":"publisher","unstructured":"Shinzato K, Takahashi Y, Yamaguchi T, Otsubo T, Nakashima K, Yoshioka G, et al. Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf332","DOI":"10.1093\/eurheartj\/ehaf332"},{"issue":"7","key":"2092_CR32","volume":"14","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14(7): e000029.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"2092_CR33","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s10741-021-10165-y","volume":"27","author":"T Agrawal","year":"2022","unstructured":"Agrawal T, Nagueh SF. Echocardiographic assessment of cardiac amyloidosis. Heart Fail Rev. 2022;27(5):1505\u201313.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"2092_CR34","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s10741-023-10332-3","volume":"28","author":"S Liang","year":"2023","unstructured":"Liang S, Liu Z, Li Q, He W, Huang H. Advance of echocardiography in cardiac amyloidosis. Heart Fail Rev. 2023;28(6):1345\u201356.","journal-title":"Heart Fail Rev"},{"issue":"9","key":"2092_CR35","doi-asserted-by":"publisher","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","volume":"35","author":"SAM Cuddy","year":"2022","unstructured":"Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, et al. Practical points for echocardiography in cardiac amyloidosis. J Am Soc Echocardiogr. 2022;35(9):A31\u201340.","journal-title":"J Am Soc Echocardiogr"},{"issue":"19","key":"2092_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovi\u0107 ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442\u20138.","journal-title":"Heart"},{"issue":"3","key":"2092_CR37","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.21037\/qims-23-1292","volume":"14","author":"PN Huang","year":"2024","unstructured":"Huang PN, Liu YN, Cheng XQ, Liu HY, Zhang J, Li L, et al. Relative apical sparing obtained with speckle tracking echocardiography is not a sensitive parameter for diagnosing light-chain cardiac amyloidosis. Quant Imaging Med Surg. 2024;14(3):2357\u201369.","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"2092_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1253\/circj.CJ-24-0472","volume":"89","author":"CY Lee","year":"2024","unstructured":"Lee CY, Nabeshima Y, Kitano T, Yang LT, Takeuchi M. Diagnostic accuracy and prognostic value of relative apical sparing in cardiac amyloidosis\u2014systematic review and meta-analysis. Circ J. 2024;89(1):16\u201323.","journal-title":"Circ J"},{"key":"2092_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031921","author":"A Mori","year":"2023","unstructured":"Mori A, Saito Y, Nakamura K, Iida T, Akagi S, Yoshida M, et al. Microcalcification and 99mTc-pyrophosphate uptake without increased bone metabolism in cardiac tissue from patients with transthyretin cardiac amyloidosis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24031921.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2092_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-024-01943-3","volume":"38","author":"H Kanaya","year":"2024","unstructured":"Kanaya H, Shiraishi S, Ogasawara K, Iwashita K, Sakamoto F, Takashio S, et al. Inverse correlation between age of onset and myocardial amyloid deposition quantified by (99m)Tc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy. Ann Nucl Med. 2024;38(9):744\u201353.","journal-title":"Ann Nucl Med"},{"issue":"24","key":"2092_CR41","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"4","key":"2092_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12149-023-01898-x","volume":"38","author":"H Guo","year":"2024","unstructured":"Guo H, Wu S, Xiang X, Wang S, Fang Z, Ye Q, et al. Performance of (99m)Tc-PYP scintigraphy in the diagnosis of hereditary transthyretin cardiac amyloidosis. Ann Nucl Med. 2024;38(4):288\u201395.","journal-title":"Ann Nucl Med"},{"issue":"11","key":"2092_CR43","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","volume":"45","author":"G Treglia","year":"2018","unstructured":"Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45(11):1945\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2092_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02292-z","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Yu C. Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis. BMC Cardiovasc Disord. 2021;21(1): 482.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2092_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.17996\/anc.24-00002","volume":"10","author":"T Saitou","year":"2024","unstructured":"Saitou T, Aikawa T, Manabe O, Fujimoto S, Matsue Y, Nagase A, et al. Lateral planar imaging of 99mTc-pyrophosphate scintigraphy in patients with suspected transthyretin cardiac amyloidosis. Ann Nucl Cardiol. 2024;10(1):29\u201337.","journal-title":"Ann Nucl Cardiol"},{"issue":"20","key":"2092_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033817","volume":"102","author":"KJ Nichols","year":"2023","unstructured":"Nichols KJ, Yoon SY, Van Tosh A, Palestro CJ. 1-hour versus 3-hour 99mTc-PYP imaging to evaluate suspected cardiac transthyretin amyloidosis. Medicine (Baltimore). 2023;102(20): e33817.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2092_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12149-022-01807-8","volume":"37","author":"T Saitou","year":"2023","unstructured":"Saitou T, Aikawa T, Manabe O, Nagase A, Kudo T, Oyama-Manabe N. Comparison of 1-h with 3-h planar (99m)Tc-pyrophosphate scintigraphy in patients with suspected transthyretin cardiac amyloidosis using SPECT as a reference standard. Ann Nucl Med. 2023;37(2):99\u2013107.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"2092_CR48","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221082","volume":"306","author":"YM Khor","year":"2023","unstructured":"Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. Tc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306(2): e221082.","journal-title":"Radiology"},{"issue":"11","key":"2092_CR49","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","volume":"22","author":"CC Quarta","year":"2021","unstructured":"Quarta CC, Zheng J, Hutt D, Grigore SF, Manwani R, Sachchithanantham S, et al. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22(11):1304\u201311.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"2092_CR50","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","volume":"14","author":"TJ Poterucha","year":"2021","unstructured":"Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution. JACC Cardiovasc Imaging. 2021;14(6):1221\u201331.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2092_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.102056","volume":"42","author":"C Godoy-Rivas","year":"2024","unstructured":"Godoy-Rivas C, Elsadany M, Jaiswal A, Weissler-Snir A, Arora S, Duvall WL. Single-photon emission computed tomography\/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis. J Nucl Cardiol. 2024;42: 102056.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2092_CR52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11604-022-01364-0","volume":"41","author":"N Matsuda","year":"2023","unstructured":"Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y, et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Jpn J Radiol. 2023;41(4):428\u201336.","journal-title":"Jpn J Radiol"},{"key":"2092_CR53","doi-asserted-by":"publisher","unstructured":"Takaishi T, Kisohara M, Horino R, Kaneko H, Hotta N, Mizuno K, et al. A quantitative SPECT\/CT metric for diagnosing transthyretin cardiac amyloidosis: multicenter study on biopsy-confirmed cases. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07294-z","DOI":"10.1007\/s00259-025-07294-z"},{"issue":"1","key":"2092_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","volume":"30","author":"L Kessler","year":"2023","unstructured":"Kessler L, Fragoso Costa P, Kersting D, Jentzen W, Weber M, L\u00fcdike P, et al. Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis. J Nucl Cardiol. 2023;30(1):101\u201311.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2092_CR55","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","volume":"28","author":"RJH Miller","year":"2021","unstructured":"Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM, et al. Diagnostic and prognostic value of technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2021;28(5):1835\u201345.","journal-title":"J Nucl Cardiol"},{"key":"2092_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25040977","author":"BC Uzuegbunam","year":"2020","unstructured":"Uzuegbunam BC, Librizzi D, Hooshyar Yousefi B. PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25040977.","journal-title":"Molecules"},{"issue":"8","key":"2092_CR57","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using (18)F-flutemetamol positron emission tomography. Ann Nucl Med. 2019;33(8):624\u20138.","journal-title":"Ann Nucl Med"},{"key":"2092_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07308-w","author":"Z Hong","year":"2025","unstructured":"Hong Z, Xue S, Yu J, Calabretta R, Haberl D, Jiang Z, et al. Total-body 11C-PIB PET\/CT imaging of systemic amyloidosis: inter-organ connectivity in cardiac amyloidosis for prognostic insights. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07308-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2092_CR59","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12149-024-02010-7","volume":"39","author":"C Okuyama","year":"2025","unstructured":"Okuyama C, Inuzuka Y, Takeuchi Y, Asagoe K, Kagawa S, Ito M, et al. Imaging of cardiac amyloidosis using dynamic (18)F-FPYBF-2 positron emission tomography. Ann Nucl Med. 2025;39(4):398\u2013403.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"2092_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10741-025-10493-3","volume":"30","author":"A Aimo","year":"2025","unstructured":"Aimo A, Ferrari Chen YF, Castiglione V, Passino C, Genovesi D, Giorgetti A, et al. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev. 2025;30(3):605\u201318.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"2092_CR61","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T, Tolbod L, Granstam SO, Eiskj\u00e6r H, Wikstr\u00f6m G, et al. Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1337\u201347.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2092_CR62","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, Katoh N, Takahashi Y, Abe R, Ezawa N, Yoshinaga T, et al. Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging. Amyloid. 2020;27(4):266\u201374.","journal-title":"Amyloid"},{"key":"2092_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07157-7","author":"Z Hong","year":"2025","unstructured":"Hong Z, Spielvogel CP, Xue S, Calabretta R, Jiang Z, Yu J, et al. Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combined 11C-PiB PET\/CT and 99mTc-DPD scintigraphy. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07157-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2092_CR64","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Kessler L, Carpinteiro A, Hagenacker T, Nensa F, Umutlu L, et al. F-Flutemetamol positron emission tomography in cardiac amyloidosis. J Nucl Cardiol. 2022;29(2):779\u201389.","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"2092_CR65","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","volume":"13","author":"JA Pan","year":"2020","unstructured":"Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging. 2020;13(6):1299\u2013310.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"2092_CR66","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/jmri.27459","volume":"53","author":"TKM Wang","year":"2021","unstructured":"Wang TKM, Brizneda MV, Kwon DH, Popovic ZB, Flamm SD, Hanna M, et al. Reference ranges, diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis: a meta-analysis. J Magn Reson Imaging. 2021;53(5):1458\u201368.","journal-title":"J Magn Reson Imaging"},{"issue":"1 Pt 1","key":"2092_CR67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","volume":"13","author":"A Baggiano","year":"2020","unstructured":"Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):69\u201380.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"25","key":"2092_CR68","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","volume":"71","author":"T Kotecha","year":"2018","unstructured":"Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2092_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","volume":"20","author":"F Ridouani","year":"2018","unstructured":"Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018;20(1):58.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2092_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14101048","author":"G Grazzini","year":"2024","unstructured":"Grazzini G, Pradella S, Bani R, Fornaciari C, Cappelli F, Perfetto F, et al. The role of T2 mapping in cardiac amyloidosis. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14101048.","journal-title":"Diagnostics"},{"issue":"5","key":"2092_CR71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017427","volume":"18","author":"M Kidoh","year":"2025","unstructured":"Kidoh M, Oda S, Takashio S, Morioka M, Kuyama N, Oguni T, et al. MRI-extracellular volume fraction versus histological amyloid load in cardiac amyloidosis: the importance of T2 mapping. Circ Cardiovasc Imaging. 2025;18(5): e017427.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"2092_CR72","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.acra.2023.08.045","volume":"31","author":"S Yamaguchi","year":"2024","unstructured":"Yamaguchi S, Oda S, Kidoh M, Hayashi H, Takashio S, Usuku H, et al. Cardiac MRI T1 and T2 mapping as a quantitative imaging biomarker in transthyretin amyloid cardiomyopathy. Acad Radiol. 2024;31(2):514\u201322.","journal-title":"Acad Radiol"},{"issue":"1","key":"2092_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12968-017-0376-0","volume":"19","author":"LK Williams","year":"2017","unstructured":"Williams LK, Forero JF, Popovic ZB, Phelan D, Delgado D, Rakowski H, et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson. 2017;19(1):61.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"6","key":"2092_CR74","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3348\/kjr.2020.0579","volume":"22","author":"JY Kim","year":"2021","unstructured":"Kim JY, Hong YJ, Han K, Lee HJ, Hur J, Kim YJ, et al. Regional amyloid burden differences evaluated using quantitative cardiac MRI in patients with cardiac amyloidosis. Korean J Radiol. 2021;22(6):880\u20139.","journal-title":"Korean J Radiol"},{"issue":"1","key":"2092_CR75","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1038\/s41598-021-94650-2","volume":"11","author":"D Korthals","year":"2021","unstructured":"Korthals D, Chatzantonis G, Bietenbeck M, Meier C, Stalling P, Yilmaz A. CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci Rep. 2021;11(1):15521.","journal-title":"Sci Rep"},{"issue":"10","key":"2092_CR76","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/ehjci\/jeae154","volume":"25","author":"D Kravchenko","year":"2024","unstructured":"Kravchenko D, Isaak A, Zimmer S, \u00d6zt\u00fcrk C, Mesropyan N, Bischoff LM, et al. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis. Eur Heart J Cardiovasc Imaging. 2024;25(10):1451\u201361.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"2092_CR77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12968-020-00690-4","volume":"22","author":"N Martini","year":"2020","unstructured":"Martini N, Aimo A, Barison A, Della Latta D, Vergaro G, Aquaro GD, et al. Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2020;22(1):84.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"2092_CR78","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jcmg.2024.09.010","volume":"18","author":"J Cockrum","year":"2025","unstructured":"Cockrum J, Nakashima M, Ammoury C, Rizkallah D, Mauch J, Lopez D, et al. Leveraging a vision transformer model to improve diagnostic accuracy of cardiac amyloidosis with cardiac magnetic resonance. JACC Cardiovasc Imaging. 2025;18(3):278\u201390.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2092_CR79","volume":"17","author":"FI Abdalla Ibrahim","year":"2025","unstructured":"Abdalla Ibrahim FI, Hussen Ali MG, Awad Ali MH, Abdalwahab Abdallah ABA, Elnoor Mohammed NG, Elhaj A, et al. The role of artificial intelligence in the detection of cardiac amyloidosis: a systematic review. Cureus. 2025;17(2): e78488.","journal-title":"Cureus"},{"issue":"10","key":"2092_CR80","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jcmg.2023.03.021","volume":"16","author":"D Han","year":"2023","unstructured":"Han D, Lin A, Kuronuma K, Gransar H, Dey D, Friedman JD, et al. Cardiac computed tomography for quantification of myocardial extracellular volume fraction: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2023;16(10):1306\u201317.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"2092_CR81","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.1007\/s00330-023-09872-x","volume":"33","author":"H Zhang","year":"2023","unstructured":"Zhang H, Guo H, Liu G, Wu C, Ma Y, Li S, et al. CT for the evaluation of myocardial extracellular volume with MRI as reference: a systematic review and meta-analysis. Eur Radiol. 2023;33(12):8464\u201376.","journal-title":"Eur Radiol"},{"issue":"5","key":"2092_CR82","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.010358","volume":"13","author":"S Oda","year":"2020","unstructured":"Oda S, Kidoh M, Takashio S, Inoue T, Nagayama Y, Nakaura T, et al. Quantification of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis. Circ Cardiovasc Imaging. 2020;13(5): e010358.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"2092_CR83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/ehjci\/jeae320","volume":"26","author":"M Kidoh","year":"2025","unstructured":"Kidoh M, Oda S, Tabata N, Kuyama N, Oguni T, Takashio S, et al. CT-derived extracellular volume fraction in aortic stenosis, cardiac amyloidosis, and dual pathology. Eur Heart J Cardiovasc Imaging. 2025;26(3):509\u201317.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"7","key":"2092_CR84","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1253\/circj.CJ-23-0948","volume":"88","author":"H Yamasaki","year":"2024","unstructured":"Yamasaki H, Kondo H, Shiroo T, Iwata N, Masuda T, Makita T, et al. Efficacy of computed tomography-based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation. Circ J. 2024;88(7):1167\u201375.","journal-title":"Circ J"},{"issue":"2","key":"2092_CR85","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222030","volume":"307","author":"GJ Aquino","year":"2023","unstructured":"Aquino GJ, O\u2019Doherty J, Schoepf UJ, Ellison B, Byrne J, Fink N, et al. Myocardial characterization with extracellular volume mapping with a first-generation photon-counting detector CT with MRI reference. Radiology. 2023;307(2): e222030.","journal-title":"Radiology"},{"key":"2092_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000001198","author":"S Popp","year":"2025","unstructured":"Popp S, Beitzke D, Strassl A, Kronberger C, Kammerlander A, Duca F, et al. Evaluation of extracellular volume and coronary artery disease in cardiac amyloidosis using photon-counting CT. Investig Radiol. 2025. https:\/\/doi.org\/10.1097\/RLI.0000000000001198.","journal-title":"Investig Radiol"},{"issue":"9","key":"2092_CR87","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9): e006075.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2092_CR88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26(1):158\u201373.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2092_CR89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jjcc.2022.02.010","volume":"80","author":"H Usuku","year":"2022","unstructured":"Usuku H, Takashio S, Yamamoto E, Yamada T, Egashira K, Morioka M, et al. Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. J Cardiol. 2022;80(1):56\u201363.","journal-title":"J Cardiol"},{"issue":"1","key":"2092_CR90","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/13506129.2023.2247136","volume":"31","author":"R Rettl","year":"2024","unstructured":"Rettl R, Calabretta R, Duca F, Binder C, Kronberger C, Willixhofer R, et al. Reduction in 99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2024;31(1):42\u201351.","journal-title":"Amyloid"},{"issue":"6","key":"2092_CR91","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","volume":"13","author":"PR Scully","year":"2020","unstructured":"Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: a novel imaging biomarker. JACC Cardiovasc Imaging. 2020;13(6):1353\u201363.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"2092_CR92","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/jcm13010284","volume":"13","author":"S Ney","year":"2024","unstructured":"Ney S, Gertz RJ, Pennig L, Nies RJ, Holtick U, V\u00f6lker LA, et al. Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment. J Clin Med. 2024;13(1):284.","journal-title":"J Clin Med"},{"issue":"3","key":"2092_CR93","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jcmg.2024.10.001","volume":"18","author":"X Wang","year":"2025","unstructured":"Wang X, Shen K, Zhang Y, Gao Y, Liu B, Guo Y, et al. Molecular stratification of light-chain cardiac amyloidosis with. JACC Cardiovasc Imaging. 2025;18(3):323\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"2092_CR94","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3348\/kjr.2023.0985","volume":"25","author":"Y Guo","year":"2024","unstructured":"Guo Y, Li X, Gao Y, Shen K, Lin L, Wang J, et al. Light-chain cardiac amyloidosis: cardiac magnetic resonance for assessing response to chemotherapy. Korean J Radiol. 2024;25(5):426\u201337.","journal-title":"Korean J Radiol"},{"issue":"45","key":"2092_CR95","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","volume":"43","author":"A Martinez-Naharro","year":"2022","unstructured":"Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022;43(45):4722\u201335.","journal-title":"Eur Heart J"},{"issue":"1","key":"2092_CR96","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with Patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189\u201399.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2092_CR97","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/ehf2.14380","volume":"10","author":"S Takashio","year":"2023","unstructured":"Takashio S, Morioka M, Ishii M, Morikawa K, Hirakawa K, Hanatani S, et al. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2023;10(4):2319\u201329.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"2092_CR98","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034518","volume":"13","author":"N Kuyama","year":"2024","unstructured":"Kuyama N, Takashio S, Oguni T, Yamamoto M, Hirakawa K, Ishii M, et al. Cardiac biomarker change at 1 year after tafamidis treatment and clinical outcomes in patients with transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2024;13(10): e034518.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2092_CR99","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023;389(3):239\u201350.","journal-title":"N Engl J Med"},{"issue":"8","key":"2092_CR100","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","volume":"14","author":"PR Huntjens","year":"2021","unstructured":"Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508\u201319.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2092_CR101","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ehjci\/jeae242","volume":"26","author":"S Istratoaie","year":"2025","unstructured":"Istratoaie S, Bourg C, Lee KC, Marut B, Antonelli J, L\u2019official G, et al. Right ventricular free wall strain predicts transthyretin amyloidosis prognosis as well as biomarker-based staging systems. Eur Heart J Cardiovasc Imaging. 2025;26(2):239\u201348.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"10","key":"2092_CR102","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.echo.2024.06.006","volume":"37","author":"B Ozbay","year":"2024","unstructured":"Ozbay B, Satyavolu BS, Rearick C, Soman P, Katz WE, Sezer A, et al. Right ventricular strain improves the echocardiographic diagnosis and risk stratification of transthyretin cardiac amyloidosis among other phenotypes of left ventricular hypertrophy. J Am Soc Echocardiogr. 2024;37(10):947\u201359.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2092_CR103","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ehjci\/jeaa097","volume":"22","author":"TS Clemmensen","year":"2021","unstructured":"Clemmensen TS, Eiskj\u00e6r H, Ladefoged B, Mikkelsen F, S\u00f8rensen J, Granstam SO, et al. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22(6):695\u2013704.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"15","key":"2092_CR104","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","volume":"149","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al. Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy. Circulation. 2024;149(15):1157\u201368.","journal-title":"Circulation"},{"key":"2092_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131892","volume":"403","author":"S Cai","year":"2024","unstructured":"Cai S, Haghbayan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, et al. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: a systematic review and meta-analysis. Int J Cardiol. 2024;403: 131892.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2092_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101135","volume":"27","author":"X Li","year":"2024","unstructured":"Li X, Guo Y, Shen K, Huang S, Gao Y, Lin L, et al. Comprehensive prognosis assessment of cardiovascular magnetic resonance parametric mapping in light chain amyloidosis. J Cardiovasc Magn Reson. 2024;27(1): 101135.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"11","key":"2092_CR107","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamacardio.2024.2555","volume":"9","author":"A Porcari","year":"2024","unstructured":"Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al. Redefining cardiac involvement and targets of treatment in systemic immunoglobulin AL amyloidosis. JAMA Cardiol. 2024;9(11):982\u20139.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2092_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101134","volume":"27","author":"L Tang","year":"2024","unstructured":"Tang L, Zhao W, Li K, Tian L, Zhou X, Guo H, et al. Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion. J Cardiovasc Magn Reson. 2024;27(1): 101134.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"11","key":"2092_CR109","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jcmg.2024.05.004","volume":"17","author":"OF Clerc","year":"2024","unstructured":"Clerc OF, Cuddy SAM, Jerosch-Herold M, Benz DC, Katznelson E, Canseco Neri J, et al. Myocardial characteristics, cardiac structure, and cardiac function in systemic light-chain amyloidosis. JACC Cardiovasc Imaging. 2024;17(11):1271\u201386.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"2092_CR110","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"2092_CR111","doi-asserted-by":"publisher","first-page":"oead092","DOI":"10.1093\/ehjopen\/oead092","volume":"3","author":"P Boretto","year":"2023","unstructured":"Boretto P, Patel NH, Patel K, Rana M, Saglietto A, Soni M, et al. Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis. Eur Heart J Open. 2023;3(5):oead092.","journal-title":"Eur Heart J Open."},{"issue":"12","key":"2092_CR112","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jcmg.2022.08.006","volume":"15","author":"F Gama","year":"2022","unstructured":"Gama F, Rosmini S, Bandula S, Patel KP, Massa P, Tobon-Gomez C, et al. Extracellular volume fraction by computed tomography predicts long-term prognosis among patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2022;15(12):2082\u201394.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2092_CR113","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1148\/radiol.2021204192","volume":"300","author":"JF Deux","year":"2021","unstructured":"Deux JF, Nouri R, Tacher V, Zaroui A, Derbel H, Sifaoui I, et al. Diagnostic value of extracellular volume quantification and myocardial perfusion analysis at CT in cardiac amyloidosis. Radiology. 2021;300(2):326\u201335.","journal-title":"Radiology"},{"issue":"22","key":"2092_CR114","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","volume":"75","author":"M Hanna","year":"2020","unstructured":"Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75(22):2851\u201362.","journal-title":"J Am Coll Cardiol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02092-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02092-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02092-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:02:55Z","timestamp":1758376975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02092-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":114,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02092-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Takashi Norikane is conducting a researcher-initiated clinical study on 18F-FMM PET\/CT in patients with ATTR-CM, supported by Nihon Medi-Physics Co., Ltd., which has provided both the radiopharmaceutical (18F-FMM) and research funding. The other authors declare no financial conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}